In a clinical study, 4 out of 9 patients with EGFR-mutant lung adenocarcinoma exhibited changed EMT status pre-and post-gefitinib treatments (Uramoto et al., 2010). The gene discussed is EGFR; the disease is lung adenocarcinoma.